- Home
- INVA
INVA
Innoviva Inc.
as 12-27-2024 4:00pm EST
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | BURLINGAME |
| Market Cap: | 1.2B | IPO Year: | 2004 |
| Target Price: | N/A | AVG Volume (30 days): | 623.4K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.99 | EPS Growth: | 46.55 |
| 52 Week Low/High: | $14.33 - $21.28 | Next Earning Date: | 11-06-2024 |
| Revenue: | $352,745,000 | Revenue Growth: | 21.46% |
| Revenue Growth (this year): | 16.2% | Revenue Growth (next year): | -0.18% |
Latest Innoviva Inc. News
INVA Breaking Stock News: Dive into INVA Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Innoviva's (NASDAQ:INVA) investors will be pleased with their 26% return over the last five years
Argus Research
5 days ago
INVA: What does Argus have to say about INVA?
Argus Research
11 days ago
INVA: Lowering target price to $19.00
TipRanks
11 days ago
Innoviva enters distribution, license agreement with Basilea for Zevtera
MT Newswires
12 days ago
Innoviva to Sell Basilea Pharmaceutica's MRSA Antibiotic Zevtera in US Under Exclusive Deal
Business Wire
12 days ago
Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)
Argus Research
18 days ago
INVA: What does Argus have to say about INVA?
Argus Research
25 days ago
INVA: What does Argus have to say about INVA?
Compare INVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INVA Innoviva Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.